PE20040764A1 - Derivados de indazol como antagonistas del factor de liberacion de corticotropina (crf) - Google Patents

Derivados de indazol como antagonistas del factor de liberacion de corticotropina (crf)

Info

Publication number
PE20040764A1
PE20040764A1 PE2003001215A PE2003001215A PE20040764A1 PE 20040764 A1 PE20040764 A1 PE 20040764A1 PE 2003001215 A PE2003001215 A PE 2003001215A PE 2003001215 A PE2003001215 A PE 2003001215A PE 20040764 A1 PE20040764 A1 PE 20040764A1
Authority
PE
Peru
Prior art keywords
alkyl
indazole
alcoxy
nrarb
aryl
Prior art date
Application number
PE2003001215A
Other languages
English (en)
Inventor
Richard Leo Cournoyer
Counde O'yang
David Garrett Loughhead
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20040764A1 publication Critical patent/PE20040764A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

SE REFIERE A DERIVADOS DE INDAZOL DE FORMULA I O II, EN DONDE R2 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C6), (CICLOALQUIL(C3-C6)-ALQUILO(C1-C3), (ALQUIL(C1-C6))CARBONILO, ALQUILSULFONILO(C1-C6), ARILO O ARILALQUILO QUE ESTAN EVENTUALMENTE SUSTITUIDOS POR ALQUILO(C1-C6), HALOALQUILO, ALCOXI (C1-C6) Y HALOGENO; R3 ES ARILO O HETEROARILO, EVENTUALMENTE SUSTITUIDOS POR DE ALQUILO(C1-C6), ALCOXI(C1-C6), ALQUILTIO(C1-C6), ALQUILSULFONILO(C1-C6), ENTRE OTROS; R1 EN EL CASO DE LA FORMULA I, ES -NRaRb, -CRcRdRe, CO2Ra o C(O)NRaRb; EN EL CASO DE LA FORMULA II ES NRaRb, CrcRdRe, CO2Ra; O EN EL CASO DE LAS FORMULAS I O II ES H, CICLOALQUENILO, ARILO O HETEROARILOQUE ESTAN EVENTUALMENTE SUSTITUIDOS POR ALQUILO(C1-C6), ALCOXI(C1-C6), ALQUILTIO(C1-C6), ALQUILSULFONILO(C1-C6), HALOGENO, ENTRE OTROS; Ra Y Rb SON H, ALQUILO(C1-C9), HIDROXIALQUILO, (ALCOXI C1-C6)-ALQUILO, ENTRE OTROS; O JUNTOS CON EL N FORMAN UN ANILLO HETEROCICLILO O HETEROARILO. SON COMPUESTOS PREFERIDOS: EL CLORHIDRATO DEL 7-(2,4-DICLORO-FENIL)-2-METIL-3-(1-PROPIL-BUT-1-ENIL)-2H-INDAZOL, CLORHIDRATO DE 2-METIL-3-(1-PROPIL-BUT-1-ENIL)-7-(2,4,6-TRIMETIL-FENIL)-2H-INDAZOL, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON ANTAGONISTAS DE RECEPTORES DEL FACTOR CRF Y PUEDEN USARSE PARA EL TRATAMIENTO DE TRANSTORNOS SIQUIATRICOS Y ENERMEDADES NEUROLOGICAS COMO LAS RELACIONADAS CON EL ESTRES, TRASTORNOS DE ANIMO, DE ALIMENTACION, DE ANSIEDAD, DISFUNCIONES GASTROINTESTINALES INDUCIDAS POR ESTRES
PE2003001215A 2002-12-02 2003-11-28 Derivados de indazol como antagonistas del factor de liberacion de corticotropina (crf) PE20040764A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43016802P 2002-12-02 2002-12-02

Publications (1)

Publication Number Publication Date
PE20040764A1 true PE20040764A1 (es) 2004-11-06

Family

ID=32469420

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001215A PE20040764A1 (es) 2002-12-02 2003-11-28 Derivados de indazol como antagonistas del factor de liberacion de corticotropina (crf)

Country Status (21)

Country Link
US (2) US7214699B2 (es)
EP (1) EP1569911B1 (es)
JP (1) JP4401298B2 (es)
KR (1) KR100761562B1 (es)
CN (1) CN100439341C (es)
AR (1) AR042148A1 (es)
AT (1) ATE399768T1 (es)
AU (1) AU2003286180B2 (es)
BR (1) BR0316950A (es)
CA (1) CA2507074A1 (es)
DE (1) DE60321958D1 (es)
ES (1) ES2309368T3 (es)
GT (1) GT200300263A (es)
MX (1) MXPA05005794A (es)
PA (1) PA8589601A1 (es)
PE (1) PE20040764A1 (es)
PL (1) PL377609A1 (es)
RU (1) RU2341518C2 (es)
TW (1) TW200418816A (es)
UY (1) UY28105A1 (es)
WO (1) WO2004050634A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
RU2376292C2 (ru) * 2003-08-14 2009-12-20 Ф.Хоффманн-Ля Рош Аг Гамк-ергические модуляторы
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
TW200616967A (en) * 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
MX2007000791A (es) * 2004-08-03 2007-03-23 Wyeth Corp Indazoles utiles en el tratamiento de enfermedades cardiovasculares.
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
WO2007115966A1 (en) * 2006-04-11 2007-10-18 F. Hoffmann-La Roche Ag Heterocyclic gaba alpha subtype selective receptor modulators
ITMI20062230A1 (it) * 2006-11-22 2008-05-23 Acraf Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2012026511A1 (ja) * 2010-08-27 2012-03-01 協和発酵キリン株式会社 医薬組成物
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
SG10202004716RA (en) * 2014-07-24 2020-06-29 Beta Pharma Inc 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
KR101713303B1 (ko) * 2015-12-24 2017-03-07 강원대학교산학협력단 2ｈ-인다졸 유도체의 제조방법
WO2022107064A1 (en) 2020-11-20 2022-05-27 Idemitsu Kosan Co., Ltd. Heterocyclic compound and an organic electroluminescence device comprising the heterocyclic compound
CN113831319A (zh) * 2021-10-19 2021-12-24 北京科技大学 含有大位阻取代基芳基硼酸/硼酸酯的铃木反应方法
KR20230081778A (ko) 2021-11-29 2023-06-08 조이운 VOCs 저감장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69323212T2 (de) * 1992-12-17 1999-05-27 Pfizer Pyrazole mit crf antagonistischer aktivität
US6005109A (en) * 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5705646A (en) * 1993-09-30 1998-01-06 Pfizer Inc. Substituted pyrazoles as CRF antagonists
US5668145A (en) * 1993-11-12 1997-09-16 Pfizer Inc. Amino-substituted pyrazoles having CRF antagonistic activity
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
US5760225A (en) * 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
JP2001521926A (ja) 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
CA2399791A1 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
CA2413002A1 (en) * 2000-06-30 2002-12-19 Banyu Pharmaceutical Co., Ltd. Novel pyrazinone derivatives
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2002016348A1 (en) * 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
US20030109550A1 (en) * 2001-09-19 2003-06-12 Michael Clare Substituted indazole compounds for the treatment of inflammation
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
TW200409759A (en) * 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols

Also Published As

Publication number Publication date
TW200418816A (en) 2004-10-01
GT200300263A (es) 2004-06-28
BR0316950A (pt) 2006-01-17
KR20050084079A (ko) 2005-08-26
US7214699B2 (en) 2007-05-08
RU2005120770A (ru) 2006-02-10
KR100761562B1 (ko) 2007-10-04
US20070213373A1 (en) 2007-09-13
JP4401298B2 (ja) 2010-01-20
RU2341518C2 (ru) 2008-12-20
WO2004050634A1 (en) 2004-06-17
ATE399768T1 (de) 2008-07-15
CN1732158A (zh) 2006-02-08
EP1569911A1 (en) 2005-09-07
CA2507074A1 (en) 2004-06-17
AR042148A1 (es) 2005-06-08
JP2006510625A (ja) 2006-03-30
MXPA05005794A (es) 2005-08-16
PA8589601A1 (es) 2004-09-16
AU2003286180A1 (en) 2004-06-23
PL377609A1 (pl) 2006-02-06
ES2309368T3 (es) 2008-12-16
US20040110815A1 (en) 2004-06-10
DE60321958D1 (de) 2008-08-14
CN100439341C (zh) 2008-12-03
AU2003286180B2 (en) 2009-11-12
EP1569911B1 (en) 2008-07-02
UY28105A1 (es) 2004-05-31

Similar Documents

Publication Publication Date Title
PE20040764A1 (es) Derivados de indazol como antagonistas del factor de liberacion de corticotropina (crf)
PE20050308A1 (es) Compuestos heterociclicos n-aril carboxamidas como inhibidores de citoquinas
US8178536B2 (en) Sirtuin modulating compounds
US8044198B2 (en) Sirtuin modulating compounds
US8093401B2 (en) Sirtuin modulating compounds
PE20040946A1 (es) Compuestos de pirazolotriazina como ligandos del receptor cannabinoide
PE20212069A1 (es) Compuesto inhibidor de jak y uso del mismo
US20070037810A1 (en) Sirtuin modulating compounds
AR060651A1 (es) Derivados de 1,2,4-triazol como moduladores de mglur5 i, intermediarios para su sintesis, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del dolor y de trastornos gastrointestinales
SE0200411D0 (sv) Novel use
ECSP066977A (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
ATE517908T1 (de) Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
PE97098A1 (es) Derivados 6,6- o 6,7 -biciclicos sustituidos que contienen pirido o pirimido
PE20060630A1 (es) Amidas sustituidas de acido tienopirrolcarboxilico, amidas del acido pirrolotiazolcarboxilico y analogos relacionados como inhibidores de la caseina cinasa ie
US20030232828A1 (en) 1-(aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
CA2218033A1 (en) Acetamide derivative, process for preparing the same, and a pharmaceutical composition containing the same
PE20051171A1 (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo
EA200500536A1 (ru) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
AR038136A1 (es) Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
PE20060632A1 (es) Derivados de arilsulfonilestilbeno como antagonistas de los receptores 5-ht2a
PE20051095A1 (es) DERIVADOS 1H-TIENO[2,3-c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA
NI200300053A (es) Derivados del tropano utiles en terapia.
PE20170083A1 (es) Nuevos compuestos
AU2009314221B2 (en) 1-(Arylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzimidazoles as 5-Hydroxytryptamine-6 Ligands
PE20081496A1 (es) Derivados de 2,5-dihidro-3-h-pirazolo[4,3-c]piridazin-3-ona sustituidos como antagonistas de los receptores cb1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal